This inventor holds 1 USPTO granted patent. Top assignee: Kinoxis Therapeutics Pty Ltd. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Damien Gulliver: Innovator in Selective Oxytocin Receptor Agonists
Introduction
Damien Gulliver is a notable inventor based in New South Wales, Australia. He has made significant contributions to the field of pharmacology, particularly in the development of selective oxytocin receptor agonists. His innovative work has the potential to impact various therapeutic areas.
Latest Patents
Damien holds 1 patent for his invention titled "Metabolite Inspired Selective Oxytocin Receptor Agonists." This patent relates to compounds of Formula I, which are cyclic metabolites of oxytocin. These derivatives exhibit enhanced selectivity for the oxytocin receptor, showcasing Damien's commitment to advancing medical science.
Career Highlights
Damien is currently associated with Kinoxis Therapeutics Pty Ltd, where he continues to explore and develop new therapeutic compounds. His work at Kinoxis Therapeutics reflects his dedication to innovation in the pharmaceutical industry.
Collaborations
Throughout his career, Damien has collaborated with esteemed colleagues, including Michael Kassiou and Tristan Reekie. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Damien Gulliver is a pioneering inventor whose work in selective oxytocin receptor agonists is paving the way for future advancements in pharmacology. His contributions are significant and reflect his expertise in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile